Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle

European Journal of Pharmacology

Volumn 374, Issue 2, 1999, Pages 249-254

  Cardelús, Ignasi ^a   Antón, Francisca ^a   Beleta, Jorge ^a   Palacios, José M ^a  

^a Res Ctr Pharmacol Dept C ^*  (Spain)

Author keywords

Desloratadine; Loratadine; Muscarinic receptor; Mydriasis; Smooth muscle, iris

Indexed keywords

ANTIHISTAMINIC AGENT; ATROPINE; CARBACHOL; CAREBASTINE; DESLORATADINE; FEXOFENADINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NPC 14695; PIRENZEPINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTICHOLINERGIC EFFECT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; MALE; MYDRIASIS; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPHINCTER PUPILLAE MUSCLE;

ANIMALS; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; IRIS; LORATADINE; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; MYDRIASIS; RABBITS; TIME FACTORS;

EID: 0033028937     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00310-6     Document Type: Article

References (29)

1. Arunlakshana A.D., Schild H.O. Some quantitative uses of drugs antagonists. Br. J. Pharmacol. 14:1959;48-54.
2. Bognar I.T., Baumann B., Dammann F., Knoll B., Meincke M., Pallas S., Fuder H. M2 muscarinic receptors on the iris sphincter muscle differ from those on iris noradrenergic nerves. Eur. J. Pharmacol. 163:1989;263-274.
3. Bognar I.T., Wesner M.T., Fuder H. Muscarine receptor types mediating autoinhibition of acetylcholine release and sphincter contraction in the guinea-pig. Naunyn-Schmiedeberg's Arch. Pharmacol. 341:1990;22-29.
4. Bognar I.T., Altes U., Beinhauer C., Kessler I., Fuder H. A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;611-618.
5. Cardelús I., Puig J., Bou J., Jáuregui J., Llenas J., Fernández A.G., Palacios J.M. Xerostomia and mydriasis, two muscarinic peripheral side effects associated with descarboethoxyloratadine, the main metabolite of loratadine. Br. J. Pharmacol. 123:1998;267P.
6. Choppin A., Eglen R.M., Hedge S.S. Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle. Br. J. Pharmacol. 124:1998;883-888.
7. Clissold S.P., Sorkin E.M., Goa K.L. Loratadine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 37:1989;42-57.
8. Davies R.J., Bagnall A.C., McCabe R.N., Calderon M.A., Wang J.H. Antihistamines: topical versus oral administration. Clin. Exp. Allergy. 26:1996;11-17.
9. Disse B., Reichl R., Speck G., Traunecker W., Rominger K.L., Hammer R. BA679BR, a novel long-acting anticholinergic bronchodilator. Life Sciences. 52:1993;537-544.
10. Disse B., Speck G., Rominger K.L., Witek T.J., Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sciences. 64:1999;457-464.
11. Eglen R.M., Hedge S.S., Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48:1996;531-565.
12. Fuder H. Functional consequences of prejunctional receptor activation or blockade in the iris. J. Ocul. Pharmacol. 10:1994;109-123.
13. Genovese A., Patella V., Decrescendo G., Dipoles A., Spader G., Mahone G. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy. 27:1997;559-567.
14. Gil D.W., Krauss H.A., Bogardus A.M., Woldemussie E. Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest. Ophthalmol. Visual Sci. 38:1997;1434-1442.
15. Handley D.A., Magnetti A., Higgins A.J. Therapeutic advantages of third generation antihistamines. Expert Opinion on Investigational Drugs. 7:1998;1045-1054.
16. Handley D.A., McCullough J.R., Fang Y., Wright S.E., Smith E.R. Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann. Allergy, Asthma Immunol. 78:1997;P164.
17. Haria M., Fitton A., Peters D.H. Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs. 48:1994;617-637.
18. Hingorani M. Drug therapy for ocular allergy. Expert Opinion on Investigational Drugs. 7:1998;27-55.
19. Howell R.E., Laemont K.D., Kovalsky M.P., Lowe V.C., Waid P.P., Kinnier W.J., Noronha-Blob L. Pulmonary pharmacology of a novel, smooth muscle-selective muscarinic antagonist in vivo. J. Pharmacol. Exp. Ther. 270:1994;546-553.
20. Ishizaka N., Noda M., Yokohama S., Kawasaki K., Yamamoto M., Higashida H. Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res. 787:1998;344-347.
21. Kaiser C., Audia V.H., Carter J.P., McPherson D.W., Waid P.P., Lowe V.C., Norohna-Blob L. Synthesis and antimuscarinic activity of some 1-cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted peperazinyl)-2-propanones and related compounds. J. Med. Chem. 36:1993;610-616.
22. Maesen F.P., Smeets J.J., Sledsens T.J., Wald F.D., Cornelissen P.J. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 8:1995;1506-1513.
23. Norohna-Blob L., Kachur J.F. Enantiomers of Oxybutynin; in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J. Pharmacol. Exp. Ther. 5:1991;562-567.
24. Tallarida, R.J., Jacobs, L., 1979, The Dose-Response Relation in Pharmacology, Springer, Berlin.
25. Vignola A.M., Crampette L., Mondain M., Sauvère G., Czarlewski W., Bousquet J., Campbell A.M. Inhibitory activity of loratadine and descarbo-ethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells. Allergy. 50:1995;200-203.
26. Weyer A., Czarlewsky W., Carmi-Leroy A., David B. In vitro inhibition by loratadine and its active metabolite of anti-IgE induced histamine release from human basophils. J. Allergy Clin. Immunol. 89:1992;222-228.
27. Woldemussie E., Feldmann B.J., Chen J. Characterization of muscarinic receptors in cultured human iris sphincter and ciliary smooth muscle cells. Exp. Eye Res. 56:1993;385-392.
28. Yoshitomi T., Ishikawa H., Haruno I., Ishikawa S. Effect of histamine and substance P on the rabbit and human iris sphincter muscle. Graefe's Arch. Clin. Exp. Ophthalmol. 233:1995;181-185.
29. Yumibe N., Huie K., Chen K., Snow M., Clement R.P., Cayen M.N. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51:1996;165-172.